Can Athira’s ACT Lift Its Share Price?
Shares of Athira Pharma Inc. (ATHA) are down nearly 62% from their all-time high of $34.25, recorded last January, and trade around $13. The company has an important catalyst to watch this year.
Athira is a late clinical-stage biopharmaceutical developing small molecules to restore neuronal health and stop neurodegeneration. The lead therapeutic candidate is ATH-1017, being developed for Alzheimer’s and Parkinson’s disease dementia.
ATH-1017 is under two clinical trials dubbed, ACT-AD and LIFT-AD.
ACT-AD is a randomized, double-blind, placebo-controlled, parallel-group phase II trial for ATH-1017 in subjects with mild-to-moderate Alzheimer’s disease.
LIFT-AD is a randomized, double-blind, placebo-controlled, parallel-group phase II/III trial for ATH-1017 in subjects with mild-to-moderate Alzheimer’s disease.
The ACT-AD study has completed enrollment with 77 subjects in the United States and Australia. Data readout from this trial, with a primary endpoint of *ERP P300 Latency and secondary endpoints measuring cognition, function, and behavior, is expected in the first half of 2022. (*The event-related brain potential (ERP) P300 component is a sensitive, noninvasive, and practical indicator of cognitive impairment).
The LIFT-AD trial is actively recruiting participants, with topline results targeted by the end of 2022.
The company is also evaluating ATH-1017 in a phase II trial for patients with Parkinson’s disease dementia or dementia with Lewy bodies, dubbed SHAPE. This study is also recruiting participants.
Next in the pipeline is ATH-1020, a novel, small molecule therapeutic for neuropsychiatric indications. This compound has completed preclinical studies, and a phase I trial of ATH-1020 in healthy volunteers is expected to be initiated next month. (Source: ClinicalTrials.gov).
The company’s cash, cash equivalents and investments were $339.4 million as of September 30, 2021.
Athira made its debut on the Nasdaq Global Select Market on September 18, 2020, offering its shares at a price of $17 each.
In the last 1 year, the stock has traded in a range of $8.88 to $34.25. ATHA closed Friday’s (Dec.31, 2021) trading at $13.03, up 5.00%.
Source: Read Full Article